Walter A Blattler

USPTO Granted Patents = 32 (Patent Applications = 19)

CIPO Patents = 3

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 4.1

ph-index = 21

Forward Citations = 3,010(Granted Patents)

Company Filing History:

17 out of 1,206

Dana-farber-cancer Institute Inc.

Children's Medical Center Corporation

where one patent can have more than one assignee

Years Active: 1985-2025

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252535 - Antibody molecules to LAG-3 and uses thereof (2025-03-18),

2. 11827704 - Antibody molecules to PD-1 and uses thereof (2023-11-28),

3. 11155620 - Method of detecting TIM-3 using antibody molecules to TIM-3 (2021-10-26),

4. 10981990 - Antibody molecules to TIM-3 and uses thereof (2021-04-20),

5. 10844135 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said (2020-11-24),

6. 10752687 - Antibody molecules to PD-1 and uses thereof (2020-08-25),

7. 10711060 - Antibody molecules to LAG-3 and uses thereof (2020-07-14),

8. 10472419 - Antibody molecules to TIM-3 and uses thereof (2019-11-12),

9. 9908936 - Antibody molecules to LAG-3 and uses thereof (2018-03-06),

10. 9884913 - Antibody molecules to TIM-3 and uses thereof (2018-02-06),

11. 9815898 - Antibody molecules to PD-1 and uses thereof (2017-11-14),

12. 9683048 - Antibody molecules to PD-1 and uses thereof (2017-06-20),

13. 9605070 - Antibody molecules to TIM-3 and uses thereof (2017-03-28),

14. 8198417 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates (2012-06-12),

15. 8163888 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates (2012-04-24),

Title: **Walter A. Blattler: Innovator in Cancer Treatment**

Introduction

Walter A. Blattler, based in Brookline, MA, has made significant contributions to the field of biomedical innovation with a remarkable portfolio of 31 patents. His work primarily revolves around antibody molecules that play critical roles in diagnosing and treating various cancers and infectious diseases.

Latest Patents

Among his latest patents are groundbreaking developments in the realm of cancer immunotherapy. The first patent involves antibody molecules specifically targeting PD-1, a protein that plays a pivotal role in suppressing the immune system. These anti-PD-1 antibody molecules offer promising applications for treating, preventing, and diagnosing cancerous and infectious conditions. Another significant patent elaborates on the methods of detecting TIM-3 using specific antibody molecules. These anti-TIM-3 antibodies have potential uses in the treatment, prevention, and diagnosis of immune-related and cancerous disorders.

Career Highlights

Walter has been integral in advancing cancer research through his roles at notable research institutions, including Dana-Farber Cancer Institute and ImmunoGen, Inc. His work has been influential in developing innovative therapeutic solutions based on the immune system's response to tumors.

Collaborations

Throughout his career, Walter has collaborated with talented professionals in the field, including Jennifer Marie Mataraza and Catherine Anne Sabatos-Peyton. Their combined efforts have further propelled advancements in antibody therapies and cancer diagnostics.

Conclusion

Walter A. Blattler's dedication to innovation and research showcases the pivotal role of inventors in medicine. His patents demonstrate not just technical expertise but a commitment to improving healthcare outcomes, especially in the fight against cancer and infectious diseases. His ongoing work promises continued advancements in the biomedical landscape.

This text is generated by artificial intelligence and may not be accurate.